A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease

Journal of Neuroimmunology

Volumn 254, Issue 1-2, 2013, Pages 63-68

  Lambracht Washington, Doris ^a   Qu, Bao Xi ^a   Fu, Min ^a   Anderson, Larry D ^a   Eagar, Todd N ^a   Stüve, Olaf ^a,c   Rosenberg, Roger N ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer disease; Amyloid beta 1 42; Antibody production; DNA vaccination; Immunotherapy; Regulatory immune response

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-42] DNA VACCINE; ANTIGEN; DNA VACCINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG SAFETY; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; MICE; MICE, INBRED STRAINS; PEPTIDE FRAGMENTS; SPLEEN; T-LYMPHOCYTES; TH2 CELLS; VACCINATION; VACCINES, DNA;

EID: 84871687263     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.09.008     Document Type: Article

References (29)

1. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(4):2023-2028.
2. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson-Wood K., Khan K., Seubert P., Freedman S., Schenk D., Games D. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25(40):9096-9101. (5).
3. DaSilva K.A., Brown M.E., McLaurin J. Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine 2009, 27(9):1365-1376.
4. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H., Agadjanyan M.G., Ghochikyan A. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010, 17(2):261-271.
5. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5(5):452-457.
6. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
7. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373(6514):523-527.
8. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
9. Hardy J. New insights into the genetics of Alzheimer's disease. Ann. Med. 1996, 28:255-258.
10. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
11. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372(9634):216-223.
12. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
13. Kim H.D., Jin J.J., Maxwell J.A., Fukuchi K. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol. Lett. 2007, 112(1):30-38.
14. Lambracht-Washington D., Qu B.X., Fu M., Eagar T.N., Stüve O., Rosenberg R.N. DNA beta-amyloid (1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302(16):1796-1802.
15. Lambracht-Washington D., Qu B.X., Fu M., Anderson L.D., Stüve O., Eagar T.N., Rosenberg R.N. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen specific Th1 and Th17 cell proliferation. Cell. Mol. Neurobiol. 2011, 31:867-874.
16. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev. Neurol. 2010, 6(2):108-119.
17. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
18. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3×Tg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One 2008, 3:2124.
19. Qu B., Rosenberg R.N., Li L., Boyer P.J., Johnston S.A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch. Neurol. 2004, 61:1859-1864.
20. Qu B., Boyer P.J., Johnston S.A., Hynan L.S., Rosenberg R.N. Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J. Neurol. Sci. 2006, 244:151-158.
21. Qu B.-X., Xiang Q., Li L., Johnston S.A., Hynan L.S., Rosenberg R.N. Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice. J. Neurol. Sci. 2007, 260:204-213.
22. Qu B.X., Lambracht-Washington D., Fu M., Eagar T.N., Stüve O., Rosenberg R.N. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine 2010, 28(32):5280-5287.
23. Rosenberg R.N. Translational research on the way to effective therapy for Alzheimer's disease. Arch. Gen. Psych. 2005, 62:1186-1192.
24. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
25. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271(31):18295-18298.
26. Serrano-Pozo A., William C.M., Ferrer I., Uro-Coste E., Delisle M.B., Maurage C.A., Hock C., Nitsch R.M., Masliah E., Growdon J.H., Frosch M.P., Hyman B.T. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010, 133(Pt 5):1312-1327.
27. Subramanian S., Divya Shree A.N. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci. Lett. 2008, 436(2):219-222.
28. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 2004, 25(2):98-104.
29. Zago W., Buttini M., Comery T.A., Nishioka C., Gardai S.J., Seubert P., Games D., Bard F., Schenk D., Kinney G.G. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J. Neurosci. 2012, 32(8):2696-2702.